Fundraisings and IPOs

* On January 8, 2014, NeoStrep, a consortium consisting of Lund University (Sweden), MinervaX (Denmark), CiToxLAB A/S (Denmark), and BioKinetic Europe Ltd. (UK), has announced  that it has been awarded € 6 million in funding under the European Commission FP7 Programme HEALTH, for the development of a novel innovative Group B Streptococcal Vaccine candidate, owned by MinervaX. The consortium is coordinated by Lund University and MinervaX is responsible for project management Together with co-funding provided by the individual partners, the funding will allow for the advancement of the GBS vaccine candidate to clinical proof of concept in Phase IIa by late 2016.

The NeoStrepvaccine candidate employs a novel innovative protein and is based on a fusion protein (GBS-NN) containing the N-terminal domains of the Rib and Alpha surface glycoproteins of GBS. The vaccine candidate has been shown to elicit a highly protective immune response in animal models of GBS infection, and is capable of neutralizing the clinically most relevant strains of GBS responsible for up to 95% of all infections (Serotypes Ia, Ib, II, III, & V) all in a single vaccine component. The vaccine candidate is currently undergoing GMP manufacturing in preparation for clinical trials to be initiated early 2015